The Delaware chemists who decided the cancer drugs that already work weren't good enough.
Spring 2026. In a brick building on Powder Mill Road - DuPont country, the old chemistry corridor of Delaware - a roughly fifty-person biotech got a phone call most startups only dream about. Novartis wanted in. Two billion dollars upfront, up to a billion more on milestones, for a single drug program spun into a subsidiary called Pikavation. Synnovation Therapeutics had existed, publicly, for barely two years.
Synnovation is not a household name. It has no consumer product, no app, no glossy mission video. What it has is a pipeline of small molecules aimed at cancer targets the industry considers settled, and a conviction that "settled" is exactly where the next breakthrough hides.
Most biotechs chase targets nobody has hit. Synnovation chases targets everybody has hit - and hits them better.
// the whole strategy, in one sentenceHere is an inconvenient truth about precision oncology: a drug can work and still disappoint. The first generation of PARP inhibitors - olaparib and its cousins - extended lives. They also hit PARP2 along with PARP1, which helped drag in hematologic toxicity. Patients got the benefit and the bruising both.
PI3K-alpha inhibitors told a similar story. Potent against the target, blunt about everything around it, limited by the side effects of hitting healthy tissue. The science was validated. The chemistry was unfinished. That gap - between a target that works and a molecule that behaves - is the entire reason Synnovation exists.
The target was never the problem. The molecule was the problem.
// the tension that runs through every programThe founders had watched this gap up close. For two decades they had been the people inside Incyte building the drugs - and seeing exactly where the drugs fell short.
Wenqing Yao spent 19 years at Incyte as head of discovery chemistry. On his watch the team produced more than 30 clinical compounds and 5 FDA-approved drugs. By any reasonable measure, he had nothing left to prove. He left anyway.
He brought company. Liangxing Wu, nearly a decade leading medicinal chemistry at Incyte, contributor to Pemazyre. Phillip Liu, two decades in biology, seventeen of them at Incyte. Kevin O'Hayer, a physician-scientist who had run an oral PD-L1 program. Their fingerprints are on drugs people take today - Olumiant, Pemazyre, Tabrecta. The bet was simple and slightly arrogant: the team that helped define these targets could redefine the molecules that hit them.
We aim to develop best-in-class therapies, ultimately aiming to enhance the lives of patients.
// Wenqing Yao, Founder & CEOThird Rock Ventures agreed, and led a $102 million Series A in January 2024. Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management came along. For a company whose lead drug hadn't yet entered a human, that is a generous vote of confidence - the kind reserved for teams who have done this before.
Wenqing Yao founds Synnovation and begins pulling together a medicinal chemistry team from his Incyte network.
Third Rock Ventures leads the round to advance a clinical-stage precision oncology pipeline.
SNV1521, a PARP1-selective inhibitor for solid tumors, enters Phase I within weeks of launch.
Novartis agrees to acquire subsidiary Pikavation Therapeutics and its PI3K-alpha asset for $2B upfront, up to $1B in milestones.
Synnovation retains its remaining R&D assets, including the next-generation PARP1 program, and keeps operating independently.
Synnovation's pipeline is short and pointed. Two lead programs, both aimed at validated targets, both engineered to fix what the first generation got wrong.
A potent, highly selective, CNS-penetrant PARP1 inhibitor with reported 500-fold selectivity over PARP2 - designed to spare the bone marrow and, critically, to follow tumors into the brain.
A mutant-selective PI3K-alpha inhibitor tuned for H1047X mutations - the program that became Pikavation, and the one Novartis paid $2B to own.
A PARP inhibitor that crosses the blood-brain barrier is a drug that refuses to lose the cancer in a crowd.
// on why CNS penetration mattersThe brain matters more than it sounds. Many cancers eventually spread there, and most first-generation PARP inhibitors simply can't reach it. A brain-penetrant PARP1 drug doesn't just treat the tumor you can see - it chases the ones that hide where other drugs won't go.
Validation in biotech is usually slow and merciless. Synnovation got the fast version. In March 2026, Novartis agreed to acquire Pikavation - the subsidiary holding SNV4818 - for $2 billion upfront and up to $1 billion in milestones, while the PI3K-alpha drug was still in Phase 1/2 for HR-positive, HER2-negative metastatic breast cancer. A Novartis executive described the asset as using "new mutant selective chemistry to more precisely target tumor biology while sparing normal cells." That is, almost word for word, Synnovation's founding thesis read back to it by one of the largest drugmakers in the world.
When the buyer quotes your own thesis back to you, you have made your point.
// on the Novartis dealAnd Synnovation kept the rest. The deal covered one program, not the company. The PARP1 franchise, the discovery pipeline, the team - all of it stays independent, now with a war chest and a track record that's hard to argue with.
The tagline is plain on purpose. Synnovation isn't selling disruption or a platform that will reinvent medicine. It is selling something narrower and harder: molecules that do the known job with fewer of the known costs. Better potency. Tighter selectivity. Drug-like properties that let a medicine reach the tissue where the cancer actually is.
It is a less romantic story than "we invented a new kind of medicine." It is also, for a patient running out of options, a more useful one.
Drug discovery rewards novelty. Conferences celebrate the never-before-drugged target, the exotic modality, the first-in-class headline. Synnovation is making the quieter bet - that there is enormous, under-appreciated value in taking a validated target and building the molecule it deserved the first time. Less glamorous. Lower biological risk. And, as Novartis just demonstrated, very far from cheap.
First-in-class gets the headline. Best-in-class gets the patient.
// the bet Synnovation is making on the futureReturn to that brick building on Powder Mill Road. Two years ago it housed an idea and a team of people who had walked away from comfortable jobs. Today it houses a validated pipeline, a $2 billion deal, and a thesis the market just confirmed in cash. The cancer drugs that already work still aren't good enough - and a small lab in Delaware is busy proving how much better they can get.